The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey

Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p <0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab’s treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p <0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data

A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment

WOS: 000262048900022PubMed ID: 1912606

Ixekizumab

Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60. It has been found effective in chronic plaque psoriasis as well as genital, hairy skin, nail, and generalized pustular psoriasis in adults. It has been approved by the FDA for use in moderate psoriasis in patients aged between 6 and 18 years

Infliximab

Infliximab is a TNF-alpha inhibitor in the form of a chimeric monoclonal antibody. It received FDA approval in 2006 for the treatment of adult patients with severe chronic plaque psoriasis who developed side effects with conventional therapies or in whom these therapies were contraindicated or did not produce any response. Infliximab is administered via intravenous infusion, and infusion reactions are one of its common side effects. It is not suitable for intermittent treatment due to the high risk of infusion reaction, risk of developing antibodies, and loss of efficacy. Infliximab has the advantage of showing rapid clinical response in the treatment of unstable psoriasis and generalized pustular psoriasis

Malassezia spp. ve dermatolojideki yeri

Pityriasis versicolor is a frequently seen superficial infection. It's clinical types are pigmented, achromic, rubra and trichromic. the agent of this disease is called Malessezia spp. which has seven types. Malassezia spp. are also responsible in different dermatologic diseases except pityriasis versicolor. These diseases can be listed as follows: seborrheic dermatitis, pityrosporum folliculitis, sebopsoriasis, Gougerout-Carteaud syndrome. Diseases which are caused by Malassezia spp. is reviewed in this Article.Dermatolojide mantar hastalıkları içinde pitiriazis versikolor sık görülen bir yüzeysel mantar enfeksiyonudur. Klinik olarak, pigmente, akromik, rubra ve trikromik tipleri bulunmaktadır. Etkeni Malassezia spp. olarak isimlendirilen ve yedi türü bulunan Malessezia türleridir. Bu etkenler, pitiriazis versikolor dışında farklı dermatolojik hastalıklardan da sorumludur. Bu hastalıklar, seboreik dermatit, pitirosporum folliküliti, sebopsoriasis, Gougerot-Carteaud sendromu şeklinde sıralanabilir. Burada dermatolojide Malassezia spp'nin sorumlu olduğu hastalıklar gözden geçirilmiştir